BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38678107)

  • 1. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
    Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
    Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
    Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
    Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
    Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
    Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
    Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of MTHFR C677T Polymorphism on High-Dose Methotrexate-Related Toxicity in Patients With Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Chang X; Guo Y; Su L; Zhang Y; Hui W; Zhao H; Hu R; Sun W
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):91-96. PubMed ID: 33069634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
    Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
    J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
    Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
    Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
    Zhao M; Liang L; Ji L; Chen D; Zhang Y; Zhu Y; Ongaro A
    Pharmacogenomics; 2016 Jun; 17(9):1005-17. PubMed ID: 27270164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
    Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
    Tsujimoto S; Yanagimachi M; Tanoshima R; Urayama KY; Tanaka F; Aida N; Goto H; Ito S
    Pediatr Blood Cancer; 2016 Nov; 63(11):1983-9. PubMed ID: 27399166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
    Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
    J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.